Amphastar Pharmaceuticals (NASDAQ:AMPH) posted its earnings results on Monday. The company reported $0.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.07 by $0.03, Briefing.com reports. The business had revenue of $60.40 million for the quarter, compared to analyst estimates of $60.62 million. Amphastar Pharmaceuticals had a net margin of 0.12% and a return on equity of 2.30%. The business’s quarterly revenue was down 4.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.01 EPS.
Shares of Amphastar Pharmaceuticals (NASDAQ AMPH) traded up $0.44 during mid-day trading on Monday, reaching $19.58. 222,059 shares of the company’s stock were exchanged, compared to its average volume of 185,731. Amphastar Pharmaceuticals has a 52-week low of $12.05 and a 52-week high of $19.95. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.08 and a quick ratio of 1.86. The firm has a market cap of $900.21, a price-to-earnings ratio of 127.60, a P/E/G ratio of 1.34 and a beta of 1.46.
AMPH has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $22.00 target price on the stock in a report on Tuesday, January 23rd. BidaskClub upgraded shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, January 19th. Piper Jaffray Companies reiterated a “buy” rating and issued a $26.00 price objective on shares of Amphastar Pharmaceuticals in a report on Tuesday, January 30th. Finally, Needham & Company LLC boosted their price objective on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $20.83.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.